Quantcast

Latest Clinical research Stories

2014-07-16 12:28:25

Cognitive function is primary endpoint COPENHAGEN, Denmark, July 16, 2014 /PRNewswire/ -- Bracket is pleased to announce that Biotie Therapies, a specialized drug development company focusing on products for neurodegenerative and psychiatric disorders, has selected the CDR System for use as the primary endpoint for their phase 2 trial of SYN120, an orally administered, dual 5HT6/5HT2a antagonist. SYN120 is in development for the treatment of Parkinson's disease and other cognitive...

2014-07-16 12:27:49

BETHESDA, Md., July 16, 2014 /PRNewswire-USNewswire/ -- The Parenteral Drug Association (PDA) has confirmed FDA's Stephen Ostroff, M.D., Acting Chief Scientist in the Office of the Commissioner will present "FDA's Views on Scientific Advances and their Impact on Manufacturing of the Future" on September 8, 2014 in at the opening plenary session of the 2014 PDA/FDA Joint Regulatory Conference in Washington, DC at the Renaissance Hotel. The Conference dates are September 8-10, 2014,...

2014-07-16 12:27:23

COSTA MESA, Calif., July 16, 2014 /PRNewswire-iReach/ -- WCCT Global, a contract research organization headquartered in Southern Californian announced today the successful completion of a large phase I clinical trial. The study protocol required that WCCT Global enroll 180 patients that would stay in their phase I Clinical Pharmacology Unit for an extended period of time. WCCT Global was able to randomize and accommodate all the needed patient cohorts without delays. WCCTG...

2014-07-16 08:28:30

DCVax®-Direct Phase II Trial Preparations and Manufacturing Expansion Underway BETHESDA, Md., July 16, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the Phase I portion of the Company's Phase I/II DCVax-Direct clinical trial has completed its 36-patient target recruitment, and the Company is now underway with preparations for the Phase II...

2014-07-15 23:14:33

Achieve is conducting a Phase III, randomized, placebo-controlled study to evaluate the safety and effectiveness of a new viscoelastic hydrogel, for the treatment of osteoarthritis of the knee. Birmingham, AL (PRWEB) July 15, 2014 *To see if you qualify for this OA Clinical Trial in Birmingham, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/) or contact us directly at (205) 380-6434. There is no cost to participate, no insurance is required, and you may receive...

2014-07-15 23:14:30

Avail is conducting a Phase 2, randomized, placebo-controlled clinical research study to evaluate the efficacy, safety and pharmacokinetics of an experimental spray treatment for qualified participants with mild to moderate osteoarthritis (OA) of the knee. DeLand, FL (PRWEB) July 15, 2014 *To see if you qualify for this Osteoarthritis Clinical Trial in DeLand, visit Avail Clinical Research on the web (http://www.availclinical.com) or contact us directly at (386) 785-2404. There is no cost...

2014-07-15 23:11:01

On July 11, the FDA alerted healthcare professionals not to use drugs marketed as sterile produced by Unique Pharmaceuticals Ltd. as they may be contaminated. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers. San Diego, CA (PRWEB) July 15, 2014 AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on Sterile Drug Products. The FDA notified...

2014-07-15 23:07:05

Announcing the Latest Version of the Market-Leading Clinical Conductor CTMS Rochester, NY (PRWEB) July 15, 2014 The Clinical Conductor CTMS team is proud to announce yet another major advancement in CTMS technology. With the latest release of Clinical Conductor, the market-leading CTMS again provides unparalleled advances in both features and functionality designed to give users even greater levels of increased efficiency and maximized profits. Most prominently seen in this release are...

2014-07-15 23:01:36

The Device Software Verification and Validation On-Demand Webinar will give attendees a clear understanding of FDA inspector expectations and how to meet them, with a specific focus on software that is as-product, in-product, process and/or in overall manufacturing and operations. Why risk FDA sanctions, let alone multimillion-dollar liability lawsuits? Falls Church, VA (PRWEB) July 15, 2014 Device Software Verification and Validation: Get Ready for a New Breed of Investigators...

2014-07-15 20:21:29

SAN DIEGO & MONROVIA, Calif., July 15, 2014 /PRNewswire/ -- Shareholder rights law firm Robbins Arroyo LLP announces that an investor of STAAR Surgical Company (NYSE: STAA) has filed a federal securities fraud class action complaint in the U.S. District Court for the Central District of California. The complaint alleges that the company and certain of its officers and directors violated the Securities Exchange Act of 1934 between February 27, 2013 and June 30, 2014 (the "Class...